BioSpace
The FDA’s extension will give reviewers more time to review a major amendment to Biogen and Eisai’s application for a subcutaneous induction formulation of Alzheimer’s therapy Leqembi.
BioSpace
The FDA's extension will give reviewers more time to review a major amendment to Biogen and Eisai's application for a subcutaneous induction formulation of Alzheimer's therapy Leqembi.
BioSpace
The FDA’s extension will give reviewers more time to review a major amendment to Biogen and Eisai’s application for a subcutaneous induction formulation of Alzheimer’s therapy Leqembi.